Rheumatology
Rheumatology guidance, immune pathway mechanisms, safety updates and trial intelligence across inflammatory arthritis and systemic autoimmune disease.
Latest Guidelines
2023 EULAR Recommendations for Systemic Lupus Erythematosus
This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations in…
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation…
2023 EULAR Recommendations for the Management of Gout
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation considerations…
Osteoarthritis: Care and Management (NICE CG177)
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before considering pharmacological interventions. Use…
Systemic Lupus Erythematosus (BSR Guidelines)
Diagnose SLE using combination of clinical features plus positive ANA with anti-dsDNA or anti-Smith antibodies, and refer to rheumatology if SLE suspected Screen all newly diagnosed…
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory markers, HLA-B27 positivity, or…
Trial Radar
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Bimekizumab long-term safety and effectiveness study in ankylosing spondylitis and related spine conditions.
PHASE2A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn’s Disease
Drug being tested: Icotrokinra, a novel therapeutic agent, is being evaluated for its efficacy and safety profile in…
PHASE3A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
What is being tested: Risankizumab pharmacokinetics (how the drug moves through the body), safety, and efficacy in paediatric…
PHASE3An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Anifrolumab (an interferon blocker) tested for safety and effectiveness in children with moderate to severe lupus.
Relevant Mechanisms
CD20 B-cell Depletion
CD20 B-cell Depletion is a clinically relevant Drug Science explainer. CD20 is a non-glycosylated phosphoprotein expressed on the surface of…
MechanismIL-6 Signalling
IL-6 Signalling is a clinically relevant Drug Science explainer. Interleukin-6 (IL-6) is a pleiotropic cytokine with both pro-inflammatory and acute-phase…
MechanismJAK-STAT Pathway
JAK-STAT Pathway is a clinically relevant Drug Science explainer. The Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway is…
MechanismRANKL/Bone Remodelling
RANKL/Bone Remodelling is a clinically relevant Drug Science explainer. Bone remodelling is maintained by the tightly coupled activity of osteoblasts…
MechanismThe IL-17/IL-23 Axis
The IL-17/IL-23 Axis is a clinically relevant Drug Science explainer. The IL-23/IL-17 axis is a central driver of immune-mediated inflammatory…
CPD, Podcasts & Webinars
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
podcastJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk…
Follow Rheumatology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Rheumatology
Choose guideline, trial, Drug Science and education updates for this specialty.